Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

The Weight Loss Drugs Market is poised for significant growth from 2025 to 2035. With increasing obesity rates, rising ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Both deputy directors at the key FDA center that oversees regulation of cancer drugs plan on leaving the agency ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...